Actelion Pharmaceuticals Ltd expressed confidence in its 2014 annual report that it can maintain its franchise in pulmonary arterial hypertension (PAH), despite the loss of exclusivity on its best-selling drug that accounts for 76% of its business. ---Subscribe to MedNous to access this article--- Company News
